SAB Biotherapeutics Inc（SABS）财务数据SABSSAB Biotherapeutics Inc

Evaluating the bottom line, SAB Biotherapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.21%, provide a clear picture of how effectively SABS converts its operational activities into shareholder value.

In the context of the broader market, SABS competes directly with industry leaders such as BNTC and AGEN. With a market capitalization of $289.35M, it holds a significant position in the sector. When comparing efficiency, SABS's gross margin of N/A stands against BNTC's N/A and AGEN's 100.00%. Such benchmarking helps identify whether SAB Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has a current ratio of 11.45, indicating strong liquidity, and it holds $217.6 million in cash, providing a runway through 2028 despite ongoing losses. The gross margin is currently at 0%, reflecting challenges in revenue generation.